6236 Stock Overview
Neith Corporation engages in the biotechnology, medical cosmetics, and preventive medicine businesses.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Neith Corporation Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | NT$35.00 |
52 Week High | NT$37.80 |
52 Week Low | NT$17.60 |
Beta | -0.022 |
1 Month Change | 6.71% |
3 Month Change | n/a |
1 Year Change | 46.44% |
3 Year Change | 284.62% |
5 Year Change | 142.21% |
Change since IPO | -88.24% |
Recent News & Updates
Shareholder Returns
6236 | TW Semiconductor | TW Market | |
---|---|---|---|
7D | 0.1% | 4.8% | 4.0% |
1Y | 46.4% | 47.3% | 28.5% |
Return vs Industry: 6236 matched the TW Semiconductor industry which returned 47.3% over the past year.
Return vs Market: 6236 exceeded the TW Market which returned 28.5% over the past year.
Price Volatility
6236 volatility | |
---|---|
6236 Average Weekly Movement | n/a |
Semiconductor Industry Average Movement | 5.7% |
Market Average Movement | 4.8% |
10% most volatile stocks in TW Market | 8.7% |
10% least volatile stocks in TW Market | 2.2% |
Stable Share Price: 6236 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 6236's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1997 | n/a | Chun Wu | www.cometruebio.com |
Neith Corporation engages in the biotechnology, medical cosmetics, and preventive medicine businesses. The company offers nutritional products, including L-One, a liquid formula for maintaining eye health; EPlus, a multiple enzyme supplement; Max Care antrodia and turmeric capsules; and Max Care natto monascus capsules, as well as other nutritional products under the King One name. It also provides genetic testing services.
Neith Corporation Fundamentals Summary
6236 fundamental statistics | |
---|---|
Market cap | NT$1.46b |
Earnings (TTM) | -NT$40.03m |
Revenue (TTM) | NT$39.90m |
36.5x
P/S Ratio-36.4x
P/E RatioIs 6236 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
6236 income statement (TTM) | |
---|---|
Revenue | NT$39.90m |
Cost of Revenue | NT$21.88m |
Gross Profit | NT$18.02m |
Other Expenses | NT$58.05m |
Earnings | -NT$40.03m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.96 |
Gross Margin | 45.16% |
Net Profit Margin | -100.33% |
Debt/Equity Ratio | 0% |
How did 6236 perform over the long term?
See historical performance and comparison